Atlas Trials

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Clinical trial NCT00846989 · COMPLETED

Trial details

NCT number
NCT00846989
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
GlaucomaOcular Hypertension
Start date
2009-01-01
Primary completion
2009-04-01
Enrollment
276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.